Aerovate Therapeutics Inc

NASDAQ AVTE

Download Data

Aerovate Therapeutics Inc Earnings Yield on June 03, 2024: -11.52%

Aerovate Therapeutics Inc Earnings Yield is -11.52% on June 03, 2024, a 17.62% change year over year. The earnings yield represents the earnings per share as a percentage of the market price per share. It is calculated by dividing income after tax by the market capitalization. This ratio provides insight into the relative value of a company's earnings in relation to its market value. A higher earnings yield may indicate a relatively undervalued stock.
  • Aerovate Therapeutics Inc 52-week high Earnings Yield is -8.53% on April 01, 2024, which is 26.00% above the current Earnings Yield.
  • Aerovate Therapeutics Inc 52-week low Earnings Yield is -1,146.02% on March 12, 2024, which is -9,844.98% below the current Earnings Yield.
  • Aerovate Therapeutics Inc average Earnings Yield for the last 52 weeks is -53.11%.
NASDAQ: AVTE

Aerovate Therapeutics Inc

CEO Mr. Timothy P. Noyes M.B.A.
IPO Date June 30, 2021
Location United States
Headquarters 930 Winter Street, Waltham, MA, United States, 02116
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email